Afleveringen
-
Part 4 of 4: In this episode, Jon Chee hosts Kate Neville, PhD, Partner at Marshall Gerstein—a law firm with over 60 years of expertise in delivering sophisticated intellectual property advice and legal services to leading businesses, research institutions, universities, and entrepreneurs worldwide.
Kate is an accomplished attorney with a doctoral background in microbiology and immunology who specializes in global patent prosecution and strategic management. She has over a decade of experience, and works with a wide range of clients, from biotech startups to big pharma to non-profits.
Kate has been recognized as a "World's Leading Patent Practitioner" by IAM magazine since 2013, an Illinois Super Lawyer since 2018, and is included in The Best Lawyers in America© for Patent Law. -
Part 3 of 4: In this episode, Jon Chee hosts Kate Neville, PhD, Partner at Marshall Gerstein—a law firm with over 60 years of expertise in delivering sophisticated intellectual property advice and legal services to leading businesses, research institutions, universities, and entrepreneurs worldwide.
Kate is an accomplished attorney with a doctoral background in microbiology and immunology who specializes in global patent prosecution and strategic management. She has over a decade of experience, and works with a wide range of clients, from biotech startups to big pharma to non-profits.
Kate has been recognized as a "World's Leading Patent Practitioner" by IAM magazine since 2013, an Illinois Super Lawyer since 2018, and is included in The Best Lawyers in America© for Patent Law. -
Zijn er afleveringen die ontbreken?
-
Part 2 of 4: Jon Chee hosts Kate Neville, Partner at Marshall Gerstein—a law firm with over 60 years of expertise in delivering sophisticated intellectual property advice and legal services to leading businesses, research institutions, universities, and entrepreneurs worldwide.
Kate, an accomplished attorney with a doctoral background in microbiology and immunology, specializes in global patent prosecution and strategic management. With over a decade of experience, she works with biotech startups, big pharma, and non-profits. Kate has been recognized as a "World's Leading Patent Practitioner" by IAM magazine since 2013, an Illinois Super Lawyer since 2018, and is included in The Best Lawyers in America© for Patent Law. -
Part 1 of 4: Jon Chee hosts Kate Neville, Partner at Marshall Gerstein—a law firm with over 60 years of expertise in delivering sophisticated intellectual property advice and legal services to leading businesses, research institutions, universities, and entrepreneurs worldwide.
Kate, an accomplished attorney with a doctoral background in microbiology and immunology, specializes in global patent prosecution and strategic management. With over a decade of experience, she works with biotech startups, big pharma, and non-profits. Kate has been recognized as a "World's Leading Patent Practitioner" by IAM magazine since 2013, an Illinois Super Lawyer since 2018, and is included in The Best Lawyers in America© for Patent Law. -
Part 4 of 4: Jon Chee hosts Barry Ticho, Founder of Verve Therapeutics and Chief Medical Officer at Stoke Therapeutics, a biotech company addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines.
With an MD PhD from the University of Chicago and extensive experience across academia and industry, Barry brings over two decades of expertise in clinical development. His journey includes roles as Head of Development at Moderna, Head of External R&D Innovation at Pfizer, and VP of Clinical Development at Biogen, where he's been instrumental in advancing numerous therapeutic programs across multiple disease areas.
Barry's unique perspective spanning academic medicine and biotechnology innovation makes his insights invaluable for aspiring leaders in the field. -
Part 3 of 4: Jon Chee hosts Barry Ticho, Founder of Verve Therapeutics and Chief Medical Officer at Stoke Therapeutics, a biotech company addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines.
With an MD PhD from the University of Chicago and extensive experience across academia and industry, Barry brings over two decades of expertise in clinical development. His journey includes roles as Head of Development at Moderna, Head of External R&D Innovation at Pfizer, and VP of Clinical Development at Biogen, where he's been instrumental in advancing numerous therapeutic programs across multiple disease areas.
Barry's unique perspective spanning academic medicine and biotechnology innovation makes his insights invaluable for aspiring leaders in the field. -
Part 2 of 4: Jon Chee hosts Barry Ticho, Founder of Verve Therapeutics and Chief Medical Officer at Stoke Therapeutics, a biotech company addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines.
With an MD-PhD from the University of Chicago and extensive experience across academia and industry, Barry brings over two decades of expertise in clinical development. His journey includes roles as Head of Development at Moderna, Head of External R&D Innovation at Pfizer, and VP of Clinical Development at Biogen, where he's been instrumental in advancing numerous therapeutic programs across multiple disease areas.
Barry's unique perspective spanning academic medicine and biotechnology innovation makes his insights invaluable for aspiring leaders in the field. -
Part 1 of 4: Jon Chee hosts Barry Ticho, Founder of Verve Therapeutics and Chief Medical Officer at Stoke Therapeutics, a biotech company addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines.
With an MD-PhD from the University of Chicago and extensive experience across academia and industry, Barry brings over two decades of expertise in clinical development. His journey includes roles as Head of Development at Moderna, Head of External R&D Innovation at Pfizer, and VP of Clinical Development at Biogen, where he's been instrumental in advancing numerous therapeutic programs across multiple disease areas.
Barry's unique perspective spanning academic medicine and biotechnology innovation makes his insights invaluable for aspiring leaders in the field. -
Part 4 of 4: Jon Chee hosts Chris Moxham, Co-Founder, CEO, and CSO of Transcripta Bio—a pioneering biotech company accelerating drug discovery to improve lives worldwide.
With a PhD in Molecular and Cellular Pharmacology from Stony Brook University and over 25 years in drug discovery, Chris brings a wealth of experience. During his two-decade tenure at Eli Lilly, he advanced over 10 molecules into clinical trials across multiple therapeutic areas, spanning both small and large molecule modalities.
Chris’s deep expertise and dedication to scientific innovation and team development offer invaluable insights for aspiring biotech leaders. -
Part 3 of 4: Jon Chee hosts Chris Moxham, Co-Founder, CEO, and CSO of Transcripta Bio—a pioneering biotech company accelerating drug discovery to improve lives worldwide.
With a PhD in Molecular and Cellular Pharmacology from Stony Brook University and over 25 years in drug discovery, Chris brings a wealth of experience. During his two-decade tenure at Eli Lilly, he advanced over 10 molecules into clinical trials across multiple therapeutic areas, spanning both small and large molecule modalities.
Chris’s deep expertise and dedication to scientific innovation and team development offer invaluable insights for aspiring biotech leaders. -
Part 2 of 4: Jon Chee hosts Chris Moxham, the Co-Founder, CEO, and CSO of Transcripta Bio, a pioneering biotech company charting a faster path in drug discovery to create better lives for people around the world.
Chris earned his PhD in Molecular and Cellular Pharmacology at Stony Brook University and is a seasoned veteran with over 25 years of drug discovery experience, having spent two decades at Eli Lilly where he was instrumental in advancing over 10 molecules into clinical trials across multiple therapeutic areas and both small and large molecule modalities.
Chris has a wealth of knowledge, and his commitment to both scientific advancement and team growth makes his insights invaluable for aspiring leaders in biotech. -
Part 1 of 4: Jon Chee hosts Chris Moxham, the Co-Founder, CEO, and CSO of Transcripta Bio, a pioneering biotech company charting a faster path in drug discovery to create better lives for people around the world.
Chris earned his PhD in Molecular and Cellular Pharmacology at Stony Brook University and is a seasoned veteran with over 25 years of drug discovery experience, having spent two decades at Eli Lilly where he was instrumental in advancing over 10 molecules into clinical trials across multiple therapeutic areas and both small and large molecule modalities.
Chris has a wealth of knowledge, and his commitment to both scientific advancement and team growth makes his insights invaluable for aspiring leaders in biotech. -
Jon Chee hosts Michael Chen, the Co-Founder and CEO of Nuclera, a biotech company that focuses on bringing rapid protein access to other labs.
Michael is a seasoned scientist and entrepreneur who brings a rich background and valuable insights to our podcast. Before co-founding Nuclera, Michael did extensive research as an undergrad student at both Georgia tech and Emory and eventually got his PhD in Chemistry from the University of Cambridge. He has also published nine scientific papers and worked with several leading scientists in their field. -
Part 1 of 2: Jon Chee hosts our latest guest, Michael Chen, the Co-Founder and CEO of Nuclera, a biotech company that focuses on bringing rapid protein access to other labs. Michael is a seasoned scientist and entrepreneur who brings his rich background and insights to our podcast.
Before becoming the Co-Founder of Nuclera, Michael did extensive research as an undergrad student at both Georgia tech and Emory and eventually got his Ph,D in Chemistry from the University of Cambridge. Having worked under some of the leading scientists in their field Michael also has 9 scientific publications to his name. His past experiences both at the lab bench and as a CEO make these episodes ones you don’t want to miss. -
Part 4 of 4:
Jon Chee hosts our latest guest, Neela Patel, Chief Business Officer at Bonum Therapeutics who are developing protein therapeutics to be used to treat a wide range of diseases. Neela is a seasoned scientist and business development executive with over 30 years of leadership experience in drug discovery and development.
Before her time at Bonum Therapeutics Neela worked as the CBO at Good Therapeutics, a biotech company that develops cutting edge protein-based drugs. Her impressive career also includes pivotal roles at Seattle Genetics, AbbVie, Abbott, and Genentech. Her extensive experience as both a scientist and business person give her unique insights you won’t want to miss. -
Part 3 of 4:
Jon Chee hosts our latest guest, Neela Patel, Chief Business Officer at Bonum Therapeutics who are developing protein therapeutics to be used to treat a wide range of diseases. Neela is a seasoned scientist and business development executive with over 30 years of leadership experience in drug discovery and development.
Before her time at Bonum Therapeutics Neela worked as the CBO at Good Therapeutics, a biotech company that develops cutting edge protein-based drugs. Her impressive career also includes pivotal roles at Seattle Genetics, AbbVie, Abbott, and Genentech. Her extensive experience as both a scientist and business person give her unique insights you won’t want to miss. -
Part 2 of 4:
Jon Chee hosts our latest guest, Neela Patel, Chief Business Officer at Bonum Therapeutics who are developing protein therapeutics to be used to treat a wide range of diseases. Neela is a seasoned scientist and business development executive with over 30 years of leadership experience in drug discovery and development.
Before her time at Bonum Therapeutics Neela worked as the CBO at Good Therapeutics, a biotech company that develops cutting edge protein-based drugs. Her impressive career also includes pivotal roles at Seattle Genetics, AbbVie, Abbott, and Genentech. Her extensive experience as both a scientist and business person give her unique insights you won’t want to miss. -
The Biotech Startups Podcast is brought to you by Excedr. Excedr provides life science startups with equipment leases on founder-friendly terms to accelerate R&D and commercialization.
Know anyone that needs lab equipment? Join Excedr’s referral program: Give Your Friends $1,000, and Earn $1,000 for Each Qualified Referral 💸.
Get your unique referral link by going to: refer.excedr.com/ZTHETY. -
Jon Chee hosts our latest guest, eMalick Njie, CEO of Ecotone AI, a healthcare company that is using AI to find cures for inherited diseases. eMalick is an experienced scientist and entrepreneur who has focused on blending his expertise in neuroscience with his knowledge of AI.
In addition to founding two AI companies, Ecotone and Genetic Intelligence, eMalick received his PhD in Neurobiology and Neuroscience from the University of Florida. His extensive and diverse experience from being a postdoctoral fellow at Columbia university to being the CEO of the AI thinktank NeuroStorm makes our conversation with him one you won’t want to miss. -
Part 3 of 4: Jon Chee hosts our latest guest, eMalick Njie, CEO of Ecotone AI, a healthcare company that is using AI to find cures for inherited diseases. eMalick is an experienced scientist and entrepreneur who has focused on blending his expertise in neuroscience with his knowledge of AI.
In addition to founding two AI companies, Ecotone and Genetic Intelligence, eMalick received his PhD in Neurobiology and Neuroscience from the University of Florida. His extensive and diverse experience from being a postdoctoral fellow at Columbia university to being the CEO of the AI thinktank NeuroStorm makes our conversation with him one you won’t want to miss. - Laat meer zien
